Biogen Inc
LSE:0R1B
Biogen Inc
LSE:0R1B
Price:
188.22
USD
-2.03%
Market Closed
Market Cap:
$27.5B
Relative Value
The Relative Value of one
0R1B
stock under the Base Case scenario is
244.42
USD.
Compared to the current market price of 188.22 USD,
Biogen Inc
is
Undervalued by 23%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
0R1B
Relative Value
Base Case
244.42
USD
Undervaluation 23%
Multiples Across Competitors
0R1B Competitors Multiples
Biogen Inc Competitors
Biogen Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Biogen Inc
LSE:0R1B
|
27.6B USD | 2.8 | 21.4 | 8.4 | 10.8 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
412.7B USD | 6.7 | 98.6 | 16.1 | 22.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
206.6B USD | 5.6 | 26.8 | 15.3 | 15.3 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
186.2B USD | 6.3 | 21.9 | 13.6 | 16.8 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
123.6B USD | 10.3 | 31.3 | 23.6 | 24.7 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
83.1B USD | 5.8 | 18.5 | 14 | 15.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
70B AUD | 3.2 | 35.5 | 11.7 | 14.7 | |
| NL |
|
argenx SE
XBRU:ARGX
|
39.8B EUR | 11.3 | 36.3 | 39.6 | 40.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
